B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
about
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsFrom BILAG to BILAG-based combined lupus assessment-30 years onEfficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy.Current status of lupus nephritis.Dual B cell immunotherapy is superior to individual anti-CD20 depletion or BAFF blockade in murine models of spontaneous or accelerated lupus.In-/off-label use of biologic therapy in systemic lupus erythematosus.Ischemic retinal vasculitis and its management.Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedsideEfficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapyInternalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosusSpotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to dateAberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.B cells participate in tolerance and autoimmunity through cytokine production.Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.New age of biological therapies in paediatric rheumatology.Republished: new age of biological therapies in paediatric rheumatology.New treatments for inflammatory rheumatic disease.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.The AP-1 Transcription Factor c-Jun Promotes Arthritis by Regulating Cyclooxygenase-2 and Arginase-1 Expression in Macrophages.The immunological barriers to xenotransplantation.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Towards new avenues in the management of lupus glomerulonephritis.Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.The therapeutic potential of plant flavonoids on rheumatoid arthritis.Systemic lupus erythematosus diagnosis and management.Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome.The quest for personalized B-cell depletion therapy in rheumatic disease.HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.
P2860
Q26774993-7E7B4D1B-2010-4928-959D-B36E2620BC65Q28081809-875417BE-21BE-403E-9701-69D8077A2B75Q33426717-83C9DE4E-BE1B-40B1-9EF0-1E150C9BAFCDQ33882751-D463A1FC-7852-4384-A2A9-80F5664D5B63Q35035048-F9DB1F36-8522-42E4-B565-8C2FD2983532Q35094536-CBB34D80-933A-467E-8261-9963703EFA32Q35170689-4E821463-746B-4812-86DF-659C1C19F6EFQ35309470-88507D00-5851-4348-9A60-4F7AEAEDD0E8Q36518986-C279870F-1003-4737-8DFD-23556E5188B2Q36532571-6AF18813-7AB7-4C26-B3B8-9AC87EF4D983Q37709763-5D913F82-85AB-4C53-A7E4-853B38FD656CQ38108851-0441AF0A-7E34-44AC-B72C-FE50C12ECCA4Q38131034-A2E0C497-DECC-453C-B097-CDE92D517300Q38150110-F7BDB3EA-2F54-487E-91BF-2E1F31548E10Q38163603-137E9421-473A-4674-82C2-86DDB7B70D06Q38184585-F0A858C8-6CA9-4CE8-AE29-7724C3E951AFQ38192656-92C45AD8-D020-4D31-859F-57A738BFA74CQ38192683-ACEA1B4F-5B9E-4491-8198-29648E53C0E8Q38195363-58A486E2-6823-46D0-AE3A-DE2A48AE168CQ38250593-7D95DF8F-EA1E-4ECC-927D-9F6AE55633D0Q38266252-E26921EB-D2E6-4F8B-B855-4BACDB5A7796Q38306720-DB2AD201-3A98-4DF7-9711-9DC1BEFF914BQ38309470-5BAB4E14-F3FD-40DA-A4DF-252A9BFFEA4FQ38396871-0A120A05-06AB-4263-A9DD-E21EE7CF6229Q38408710-B1866E81-B5FA-4C74-9C7C-098AD5E41A1DQ38435899-0D218683-21BB-4C57-A987-19FAF564B91CQ38588520-4173F82F-DD53-4093-A793-653874711DA0Q38590248-95C2CDBF-164F-4E33-BDF2-CDA98BAEDE7CQ38686467-D4319F19-0BBD-4D6B-B91E-EA263B3554A7Q38690844-4F10E922-DC87-44B9-8980-1AA1196806F5Q38934748-9539985F-202E-48FC-BBB5-D833314D6B3CQ38979169-1EED596F-0654-45B8-93BA-FFBD58DA7FDDQ39016582-5436797C-3D8F-4F1C-9C3A-65E41402DCD5Q39053129-D265A55E-3150-4F9E-A6AF-B0CDA4EF39E5Q39410103-A8AA8CE1-591D-4E78-9987-952F0D78874BQ41124267-384910A3-2C6A-4E8B-A958-B055CC443250Q41482035-57D53842-CBEB-4507-9C16-10238A912A58Q41670053-90D14723-0E50-440D-B06B-9F7F8CF69843Q42356199-799F9601-F51B-4FE9-823F-4DA92604ACB6Q47837398-DE570F81-4C2D-429C-B7D7-39220677830A
P2860
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
B-cell depletion in SLE: clini ...... implications for study design.
@en
B-cell depletion in SLE: clini ...... implications for study design.
@en-gb
type
label
B-cell depletion in SLE: clini ...... implications for study design.
@en
B-cell depletion in SLE: clini ...... implications for study design.
@en-gb
prefLabel
B-cell depletion in SLE: clini ...... implications for study design.
@en
B-cell depletion in SLE: clini ...... implications for study design.
@en-gb
P2093
P2860
P921
P356
P1476
B-cell depletion in SLE: clini ...... implications for study design.
@en
P2093
David Close
David Jayne
Venkat Reddy
P2860
P2888
P356
10.1186/AR3910
P478
15 Suppl 1
P5008
P577
2013-02-11T00:00:00Z